Hybrid deep learning technique for COX-2 inhibition bioactivity detection against breast cancer disease

Biomed Eng Lett. 2024 Apr 10;14(4):631-647. doi: 10.1007/s13534-024-00355-6. eCollection 2024 Jul.

Abstract

This study addresses detecting COX-2 inhibition in breast cancer, targeting its role in tumor growth. The primary goal is to develop an efficient technique for precise COX-2 inhibition bioactivity detection, with implications for identifying anti-cancer compounds and advancing breast cancer therapies. The proposed methodology uses the UNet architecture for feature extraction, enhancing accuracy. A modified chicken swarm optimization (MCSO) algorithm addresses data dimensionality, optimizing features. An improved Laguerre neural network (ILNN) classifies COX-2 inhibition bioactivity. Validation is performed using the ChEMBL database. The research evaluates the accuracy, precision, recall, F-measure, Matthews' correlation coefficient (MCC), and Dice coefficient of the proposed method. These metrics are compared against those of contemporary methods to assess the efficiency and effectiveness of the developed technique. The study underscores the hybrid deep learning method's significance in accurately detecting COX-2 inhibition bioactivity against breast cancer. Results highlight its potential as a valuable tool in breast cancer drug discovery.

Keywords: Bioactivity detection; Breast cancer; COX-2 inhibition; Data dimensionality; Feature extraction.